Regarding therapy that targets fatty acid metabolism, some studies have proved that TVB-3166 and TVB-2640, fatty acid synthase (FASN) inhibitors, have anti-tumor effects in preclinical colorectal and breast cancer models, as well as limited systemic toxicity and favorable tolerability in early-phase clinical trials (78, 79). This evidence concerns the gene FASN and neoplasm.